Stochastic Interpolation of Precipitation Data From Multiple Sensors

Introduction: This report summarizes the work conducted under Grant No. ECE-8419189, Stochastic Interpolation of Precipitation Data from Multiple Sensors, which was awarded to Utah State University in September, 1985, and completed February 29, 1988. it also covers work under a supplemental award made in February, 1986. The final report is organized into four sections. The following section presents the objective of the research and a brief problem statment. Section 3 contains a summary of second-year work including the project team, work plan, work completed, and publications. In Section4, project conclusions are summarized. A summary of on-going future work is given in Section 5, together with our plans for publication of research results from this project. Copies of preliminary draft manuscripts and completed technical reports which have been prepared as a result of second-year activities are contained in the Appendices. A cummulative summary of project publications is presented in Appendix A

The Exomars Climate Sounder (EMCS) Investigation

The ExoMars Climate Sounder (EMCS) investigation is developed at the Jet Propulsion Laboratory (Principal Investigator J. T. Schofield) in collaboration with an international scientific team from France, the United Kingdom and the USA. EMCS plans to map daily, global, pole-to-pole profiles of temperature, dust, water and CO2 ices, and water vapor from the proposed 2016 ExoMars Trace Gas Orbiter (EMTGO). These profiles are to be assimilated into Mars General Circulation Models (MGCMs) to generate global, interpolated fields of measured and derived parameters such as wind

Physics at a Fermilab Proton Driver

This report documents the physics case for building a 2 MW, 8 GeV superconducting linac proton driver at Fermilab.Comment: 52 pages, 15 figure

Viral Endomyocardial Infection Is an Independent Predictor and Potentially Treatable Risk Factor for Graft Loss and Coronary Vasculopathy in Pediatric Cardiac Transplant Recipients

ObjectivesThis study sought to evaluate the outcome and prevalence of viral endomyocardial infection after cardiac transplantation.BackgroundViral myocardial infection causes heart failure, but its role after cardiac transplantation is unclear. We hypothesized that viral infection of the cardiac allograft reduces graft survival.MethodsBetween June 1999 and November 2004, 94 pediatric cardiac transplant patients were screened for the presence of viral genome in serial endomyocardial biopsies (EMBs) using polymerase chain reaction (PCR) assays. Graft loss, advanced transplant coronary artery disease (TCAD), and acute rejection (AR) were compared in the PCR-positive (n = 37) and PCR-negative (n = 57) groups, using time-dependent Kaplan-Meier and Cox regression analyses. From November 2002 to November 2004, intravenous immunoglobulin therapy (IVIG) was administered to patients with PCR-positive EMBs. The outcomes of the IVIG-treated, PCR-positive patients (n = 20) were compared with IVIG-untreated, PCR-positive patients (n = 17).ResultsViral genomes were detected in EMBs from 37 (39%) patients; parvovirus B19, adenovirus, and Epstein-Barr virus (EBV) were the most common. The PCR-positive group (n = 37, 25% graft loss at 2.4 years) had decreased graft survival (p < 0.001) compared with the PCR-negative group (n = 57, 25% graft loss at 8.7 years) and developed advanced TCAD prematurely (p = 0.001). The number of AR episodes was similar in both groups. On multivariate analysis, presence of viral genome was an independent risk factor for graft loss (relative risk: 4.2, p = 0.015). The time to advanced TCAD after becoming PCR-positive was longer in the IVIG-treated patients (p = 0.03) with a trend toward improved graft survival (p = 0.06).ConclusionsViral endomyocardial infection is an independent predictor of graft loss in pediatric cardiac transplant recipients. This effect appears to be mediated through premature development of advanced TCAD. IVIG therapy in this subgroup may improve survival and merits further investigation

The BNO-LNGS joint measurement of the solar neutrino capture rate in 71Ga

We describe a cooperative measurement of the capture rate of solar neutrinos by the reaction 71Ga(\nu_e,e^-)71Ge. Extractions were made from a portion of the gallium target in the Russian-American Gallium Experiment SAGE and the extraction samples were transported to the Gran Sasso laboratory for synthesis and counting at the Gallium Neutrino Observatory GNO. Six extractions of this type were made and the resultant solar neutrino capture rate was 64 ^{+24}_{-22} SNU, which agrees well with the overall result of the gallium experiments. The major purpose of this experiment was to make it possible for SAGE to continue their regular schedule of monthly solar neutrino extractions without interruption while a separate experiment was underway to measure the response of 71Ga to neutrinos from an 37Ar source. As side benefits, this experiment proved the feasibility of long-distance sample transport in ultralow background radiochemical experiments and familiarized each group with the methods and techniques of the other.Comment: 7 pages, no figures; minor additions in version

Measurement of the Solar Neutrino Capture Rate by the Russian-American Gallium Solar Neutrino Experiment During One Half of the 22-Year Cycle of Solar Activity

We present the results of measurements of the solar neutrino capture rate in gallium metal by the Russian-American Gallium Experiment SAGE during slightly more than half of a 22-year cycle of solar activity. Combined analysis of the data of 92 runs during the 12-year period January 1990 through December 2001 gives a capture rate of solar neutrinos with energy more than 233 keV of 70.8 +5.3/-5.2 (stat.) +3.7/-3.2 (syst.) SNU. This represents only slightly more than half of the predicted standard solar model rate of 128 SNU. We give the results of new runs beginning in April 1998 and the results of combined analysis of all runs since 1990 during yearly, monthly, and bimonthly periods. Using a simple analysis of the SAGE results combined with those from all other solar neutrino experiments, we estimate the electron neutrino pp flux that reaches the Earth to be (4.6 +/- 1.1) E10/(cm^2-s). Assuming that neutrinos oscillate to active flavors the pp neutrino flux emitted in the solar fusion reaction is approximately (7.7 +/- 1.8) E10/(cm^2-s), in agreement with the standard solar model calculation of (5.95 +/- 0.06) E10/(cm^2-s).Comment: English translation of article submitted to Russian journal Zh. Eksp. Teor. Fiz. (JETP); 12 pages, 5 figures. V2: Added winter-summer difference and 2 reference

Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: Results from MyPathway, a phase IIa multiple basket study

BACKGROUND: Systemic therapy options for salivary cancers are limited. MyPathway (NCT02091141), a phase IIa study, evaluates targeted therapies in non-indicated tumor types with actionable molecular alterations. Here, we present the efficacy and safety results for a subgroup of MyPathway patients with advanced salivary gland cancer (SGC) matched to targeted therapies based on tumor molecular characteristics. PATIENTS AND METHODS: MyPathway is an ongoing, multiple basket, open-label, non-randomized, multi-center study. Patients with advanced SGC received pertuzumab + trastuzumab (HER2 alteration), vismodegib (PTCH-1/SMO mutation), vemurafenib (BRAF V600 mutation), or atezolizumab [high tumor mutational burden (TMB)]. The primary endpoint is the objective response rate (ORR). RESULTS: As of January 15, 2018, 19 patients with SGC were enrolled and treated in MyPathway (15 with HER2 amplification and/or overexpression and one each with a HER2 mutation without amplification or overexpression, PTCH-1 mutation, BRAF mutation, and high TMB). In the 15 patients with HER2 amplification/overexpression (with or without mutations) who were treated with pertuzumab + trastuzumab, 9 had an objective response (1 complete response, 8 partial responses) for an ORR of 60% (9.2 months median response duration). The clinical benefit rate (defined by patients with objective responses or stable disease \u3e4 months) was 67% (10/15), median progression-free survival (PFS) was 8.6 months, and median overall survival was 20.4 months. Stable disease was observed in the patient with a HER2 mutation (pertuzumab + trastuzumab, n = 1/1, PFS 11.0 months), and partial responses in patients with the PTCH-1 mutation (vismodegib, n = 1/1, PFS 14.3 months), BRAF mutation (vemurafenib, n = 1/1, PFS 18.5 months), and high TMB (atezolizumab, n = 1/1, PFS 5.5+ months). No unexpected toxicity occurred. CONCLUSIONS: Overall, 12 of 19 patients (63%) with advanced SGC, treated with chemotherapy-free regimens matched to specific molecular alterations, experienced an objective response. Data from MyPathway suggest that matched targeted therapy for SGC has promising efficacy, supporting molecular profiling in treatment determination

First Measurement of the Neutron β\beta-Asymmetry with Ultracold Neutrons

We report the first measurement of angular correlation parameters in neutron $\beta$-decay using polarized ultracold neutrons (UCN). We utilize UCN with energies below about 200 neV, which we guide and store for $\sim 30$ s in a Cu decay volume. The $\vec{\mu}_n \cdot \vec{B}$ potential of a static 7 T field external to the decay volume provides a 420 neV potential energy barrier to the spin state parallel to the field, polarizing the UCN before they pass through an adiabatic fast passage (AFP) spin-flipper and enter a decay volume, situated within a 1 T, $2 \times 2\pi$ superconducting solenoidal spectrometer. We determine a value for the $\beta$-asymmetry parameter $A_0$, proportional to the angular correlation between the neutron polarization and the electron momentum, of $A_0 = -0.1138 \pm 0.0051$.Comment: 4 pages, 2 figures, 1 table, submitted to Phys. Rev. Let

A Comprehensive Resource for Induced Pluripotent Stem Cells from Patients with Primary Tauopathies.

Primary tauopathies are characterized neuropathologically by inclusions containing abnormal forms of the microtubule-associated protein tau (MAPT) and clinically by diverse neuropsychiatric, cognitive, and motor impairments. Autosomal dominant mutations in the MAPT gene cause heterogeneous forms of frontotemporal lobar degeneration with tauopathy (FTLD-Tau). Common and rare variants in the MAPT gene increase the risk for sporadic FTLD-Tau, including progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). We generated a collection of fibroblasts from 140 MAPT mutation/risk variant carriers, PSP, CBD, and cognitively normal controls; 31 induced pluripotent stem cell (iPSC) lines from MAPT mutation carriers, non-carrier family members, and autopsy-confirmed PSP patients; 33 genome engineered iPSCs that were corrected or mutagenized; and forebrain neural progenitor cells (NPCs). Here, we present a resource of fibroblasts, iPSCs, and NPCs with comprehensive clinical histories that can be accessed by the scientific community for disease modeling and development of novel therapeutics for tauopathies